Sponsored by
This is a potential game changer. These authors looked for biomarkers that can predict success for Optune users, and found that a score composed of 3 biomarkers could differentiate between patients who do exceedingly well and those that do not. The difference is tremendous: If your score was high, overall survival with Optune was about 82% at 45 months, compared to about 16% without Optune.
Of course I would love for this to be validated in another group of patients but the difference is so large we should consider it now when making decisions.
If you have a high score, it makes sense to use Optune instead of a clinical trial that doesn't allow Optune use, No clinical trial has ever shown the results this study has.
If you have a low score, either enter a clinical trial, or use Optune but add treatments that counteract the biomarkers..
These results were for Optune patients with poor compliance and were stll impressive. I would love to see the results with high compliance.